The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants.

ABSTRACT:

Background

Pregnant and breastfeeding women (PBW) in sub-Saharan Africa have high HIV incidence rates and associated risk of vertical transmission to their infants. Oral preexposure prophylaxis (PrEP) and injectable PrEP (long-acting cabotegravir, or CAB-LA) can potentially reduce this HIV transmission, but population-level impacts are uncertain.

Methods

We extended a previously developed model of HIV and PrEP in South Africa to allow for variable PrEP duration and preference in PBW. We considered three potential scenarios for PrEP provision to PBW: oral PrEP only, CAB-LA only, and allowing oral/CAB-LA choice, with uptake and retention assumptions informed by South African data, each compared with a 'base' scenario without PrEP for PBW.

Results

Without PrEP for PBW, t

SUBMITTER: Johnson LF 

PROVIDER: S-EPMC10906189 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature